Used as a chiral building block in the synthesis of pharmaceutical intermediates, particularly in the development of protease inhibitors and other bioactive molecules. Its structure contains both a fluorenylmethyloxycarbonyl (Fmoc) protecting group and a chiral center, making it valuable in solid-phase peptide synthesis and asymmetric synthesis. The presence of the methoxyphenyl moiety can enhance binding selectivity in target molecules, and it is often employed in the preparation of enzyme inhibitors where stereochemistry plays a critical role in activity. Commonly utilized in research settings for drug discovery and development, especially in oncology and antiviral therapies.